What Applied DNA Sciences does

Applied DNA Sciences, now operating as BNB Plus Corporation (NASDAQ: BNBX, formerly APDN), is a Delaware-incorporated biotechnology company that has undergone a radical strategic transformation in 2025. Historically it sold botanical DNA-based anti-counterfeiting and supply chain authentication services (CertainT, SigNature DNA, fiberTyping) targeting textiles, pharmaceuticals and cannabis; today its commercial center of gravity is the LineaRx subsidiary, which produces enzymatically-synthesized linear DNA (LineaDNA) using proprietary large-scale PCR for mRNA production, gene therapy, cell therapy and veterinary vaccine applications. The Linea IVT platform combines LineaDNA IVT templates with a proprietary chemically-modified RNA polymerase (Linea RNAP, acquired from Spindle Biotech in July 2023) to address plasmid DNA bottlenecks and dsRNA contamination in mRNA manufacturing, and is supported by cGMP-certified production capacity in Stony Brook, NY, a Notice-of-Allowance on the Linea RNAP composition patent (protection into 2041), and a 70%+ manufacturing cost reduction achieved through the Alphazyme partnership.

The company generates revenue through B2B direct enterprise sales of LineaDNA products and custom manufacturing services to pharmaceutical companies, biotech firms, CDMOs and IVD manufacturers, supplemented by authentication services under multi-year contracts; pricing is quote-based and not publicly disclosed. Named enterprise customers include ÚHKT (CAR T Phase I trial), a Global IVD Manufacturer, Kudo Biotechnology, a Top-20 pharmaceutical manufacturer, an APAC-based mRNA CDMO and a US CRISPR/mRNA therapeutics developer, with veterinary research conducted alongside Cornell University. In June 2025 the company closed Applied DNA Clinical Labs and executed a 27% workforce reduction to focus resources on LineaRx; subsequently it rebranded as BNB Plus Corporation, changed its NASDAQ ticker to BNBX and committed up to $58M in private placement proceeds to a BNB cryptocurrency digital asset treasury strategy, pivoting its capital deployment away from pure biotech operations while retaining the LineaRx business as a continuing operating segment.

Name

Applied DNA Sciences

Legal name

Applied DNA Sciences, Inc.

Website

https://adnas.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Applied DNA Sciences (now BNB Plus Corporation, NASDAQ: BNBX) sells PCR-produced LineaDNA and the Linea IVT mRNA manufacturing platform to pharma, biotech, CDMO and IVD customers via its LineaRx subsidiary, while increasingly deploying capital into a BNB cryptocurrency treasury strategy following its 2025 strategic pivot.

Ownership category

akta.pro rank

Headquarters

HQ city

Stony Brook

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Therapeutic DNA Production (LineaRx): Sale of LineaDNA products for use in mRNA production, gene therapy, cell therapy, and veterinary medicine applications. Revenue from IVT templates and related products for biotherapeutic manufacturing.
2. Molecular Diagnostics Testing Services (Applied DNA Clinical Labs): PCR-based DNA and RNA detection services for molecular diagnostics and genetic testing, including COVID-19 surveillance and pharmacogenomic testing
3. Supply Chain Security and Authentication: DNA-based authentication services (CertainT, SigNature, fiberTyping) for industrial supply chain security including textiles, pharmaceuticals, and cannabis

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Applied DNA Sciences, through its LineaRx subsidiary, manufactures enzymatically-produced linear DNA (LineaDNA) via proprietary large-scale PCR for use in mRNA production, gene therapy, and cell therapy applications. The company also offers DNA-based supply chain authentication services (CertainT, SigNature DNA, fiberTyping) for textiles, pharmaceuticals, and cannabis, and operates a cGMP manufacturing facility for therapeutic DNA production.

Product overview

Applied DNA Sciences operates primarily through its LineaRx subsidiary, offering a portfolio centered on enzymatic DNA production. The core offering is the LinearDNA platform—a cell-free PCR-based DNA manufacturing system that produces high-fidelity DNA constructs (100bp to 20kb) as an alternative to plasmid-based production. This platform feeds into the Linea IVT platform, which combines LinearDNA with proprietary Linea RNAP for mRNA and saRNA manufacturing. The company previously operated Applied DNA Clinical Labs (now ceased) for molecular diagnostics, and maintains CertainT/SigNature DNA authentication services for supply chain security. Recent strategic shift includes pivot to BNB cryptocurrency treasury management.

Differentiator

Problem solved

Functional benefit

Brands

• LineaDNA: Enzymatically-produced linear DNA platform for nucleic acid-based therapeutics including mRNA production, gene therapy, and cell therapy applications
• LineaIVT
• LineaRx
• CertainT

Products and services

• LineaRx Majority-owned subsidiary focused on enzymatic production of LinearDNA for use in mRNA production, gene therapy, cell therapy, and advanced therapeutic modalities.
• LineaDNA (LinearDNA) Enzymatically-produced linear DNA manufactured via proprietary large-scale PCR-based platform. Produces high-fidelity DNA constructs ranging from 100bp to 20kb in quantities from milligrams to grams, free of adventitious DNA sequences. Alternative to plasmid-based DNA manufacturing.
• Linea IVT Platform Combines enzymatically-produced LineaDNA IVT templates with proprietary Linea RNA polymerase (RNAP) to enable mRNA and saRNA manufacturers to produce high-quality mRNA faster, eliminating plasmid DNA as starting material and reducing dsRNA contamination.
• Linea RNAP Proprietary chemically-modified RNA polymerase enzyme acquired from Spindle Biotech. Core component of the Linea IVT platform enabling mRNA manufacturers to produce better mRNA faster with reduced dsRNA contamination. US patent protection expected into 2041.
• cGMP LinearDNA Production GMP-compliant manufacturing capabilities for therapeutic DNA production. Facility integrates rapid enzymatic PCR-based DNA production within cGMP framework ensuring thorough documentation and QC analysis, supporting transition from discovery to clinical and commercial applications.
• CertainT Authentication DNA-based authentication platform for supply chain security enabling verification of product authenticity through genetic polymorphism, molecular taggants, isotopic signatures, or other identifiers. Covers textile authentication, supply chain security, and anti-counterfeiting applications.
• SigNature DNA Proprietary DNA genotyping and mass-spectrometry based authentication service for identifying and verifying materials throughout supply chains. Uses molecular taggants for product authentication and supply chain integrity verification.
• fiberTyping DNA-based fiber authentication service for textile supply chain verification, enabling identification of fiber composition and origin to prevent counterfeiting and ensure quality control.
• LinearDNA-LNP Vaccine Platform Lipid nanoparticle delivery system for LinearDNA constructs enabling intramuscular administration without electroporation. Enables therapeutic applications including cancer vaccines, protein replacement, and cell/gene therapies with simplified delivery compared to traditional approaches.
• TR8 PGx Pharmacogenomic sub-panel for indication-specific use, complementing full-panel testing. First sub-panel launched for Pre-emptive Oncology Care relating to fluoropyrimidine-based cancer therapeutics.

Quantifiable outcome

• Over 70% reduction in Linea RNAP manufacturing costs
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and secondary.

• ÚHKT (Institute of Hematology and Blood Transfusion)coreStrategic or Co-development Partner · 18 December 2024ÚHKT utilizing Linea DNA as critical component in CD123-specific CAR T-cell therapy manufacturing. Linea DNA enables non-viral workflow to reduce manufacturing costs and timelines. Phase I clinical trial approved by Czech regulatory authority.
• HDT BiosecondaryStrategic or Co-development Partner · 25 April 2024Awarded contract for rapid vaccine development program
• Alphazyme LLC (Maravai LifeSciences)coreTechnology or Integration · 18 March 2024Manufacturing scale-up agreement for Linea RNAP. Alphazyme performed manufacturing process development to scale Linea RNAP from research to commercial scale. Project resulted in over 70% reduction in manufacturing costs and quantity sufficient for near-term demand.
• Kudo BiotechnologycoreStrategic or Co-development Partner · 14 December 2023Joint development agreement to integrate Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. Companies seeking to optimize mRNA quality, yields, and dsRNA mitigation at manufacturing scale. Plans for global co-marketing relationship.
• Cornell University College of Veterinary MedicinesecondaryStrategic or Co-development Partner · 14 September 2023Sponsored research agreement for translational research to accelerate development of LineaDNA-LNP veterinary vaccine platform. Evaluating multiple LNP formulations and DNA sequence optimization for maximum immunogenicity.
• Spindle BiotechcoreTechnology or Integration · 13 July 2023Acquisition of Spindle Biotech for RNA manufacturing technology. Acquired Linea RNAP technology and expertise to expand mRNA production capabilities and address dsRNA contamination issues.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• GenScript: GenScript provides gene synthesis, plasmid manufacturing, and protein services to therapeutic developers, overlapping Applied DNA's enzymatic DNA production for mRNA and gene therapy customers. Both target pharma/biotech CDMO and academic customers with custom DNA and RNA products.
• Aldevron (Danaher): Aldevron is a CDMO producing plasmid DNA, mRNA, and proteins for cell and gene therapy developers. It competes head-on with Applied DNA's LineaRx offering as a supplier of DNA inputs to gene therapy and cell therapy manufacturers.
• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading mRNA and nucleic acid CDMO that manufactures IVT templates, mRNA, and CleanCap capping analog — directly overlapping Applied DNA's LineaDNA IVT and Linea IVT platform offering for mRNA therapeutics developers. Both target the same CDMO and therapeutic developer customer base.
• Eurofins Genomics: Eurofins Genomics provides commercial DNA synthesis, gene synthesis, and sequencing services to pharmaceutical, biotech, and academic customers. It competes directly with Applied DNA's PCR-based LinearDNA product in the custom synthetic DNA market.
• Twist Bioscience: Twist Bioscience offers silicon-based DNA synthesis and is a direct competitor in synthetic DNA manufacturing for mRNA, gene therapy, and synthetic biology applications. Like Applied DNA, Twist serves pharma, biotech, and academic customers with high-fidelity synthetic DNA, but at significantly greater scale.
• Integrated DNA Technologies (IDT, Danaher): IDT is one of the largest commercial manufacturers of custom DNA and RNA oligos and gene synthesis services, with a comparable customer base in pharma, biotech, and academic research. Applied DNA competes with IDT in PCR-based synthetic DNA and oligo production for therapeutics and diagnostics.

Broad incumbents

• BioNTech: BioNTech is an mRNA therapeutics developer and manufacturer that both consumes IVT DNA inputs (overlapping with Applied DNA's customer base) and is developing proprietary manufacturing capabilities that could substitute for external CDMOs like LineaRx.
• Thermo Fisher Scientific: Thermo Fisher is a broad life sciences incumbent whose bioscience tools and bioproduction businesses (including Patheon CDMO services) overlap heavily with Applied DNA's DNA/mRNA manufacturing and authentication offerings. It dwarfs Applied DNA in scale and acts as a large competitor in supply chain authentication and molecular biology tools.

Emerging players

• Codexis: Codexis engineers enzymes and biocatalysts for nucleic acid and small molecule manufacturing, including DNA/RNA synthesis applications. Its enzyme engineering capability is adjacent to Applied DNA's Linea RNAP and PCR-based enzymatic DNA approach and could become a competitor or partner in enzyme-based nucleic acid manufacturing.

Regional players

• AlpVision: AlpVision provides digital and covert marking-based anti-counterfeiting and authentication solutions for pharmaceuticals and consumer goods, directly overlapping Applied DNA's CertainT/SigNature DNA authentication offering for supply chain security.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• Xx.com/APDN
• LinkedInlinkedin.com/company/73050
• Facebookfacebook.com/111545158923349

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds18 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Applied DNA Sciences